Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... program of drug provision for patients suffering from 7 certain diseases and health states including organ ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... obstructive bronchitis in children. The original drug Augmentin (Smithkline Beecham Pharmaceuticals ..."
 
Vol 10, No 3 (2017) Decision modelling for the evaluation of diabetes outcomes Abstract  similar documents
A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin
"... or to some aspects of the disease. Thus, the use of the novel anti-diabetic drugs (liraglutide, semaglutide ..."
 
Vol 11, No 2 (2018) Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations Abstract  similar documents
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
"... in the costs of different drug therapy regimens. ..."
 
Vol 13, No 4 (2020) Concept of value-based healthcare Abstract  similar documents
N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov
"... processes including procurement of drugs and medical devices, their pricing, and reimbursement. ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... of registration in the case of inclusion in the Essential Drugs List (0,5% R-R amp. 10 ml №10 – 947,74 RUB; 0 ..."
 
Vol 7, No 2 (2014) CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM Abstract  similar documents
I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek
"... , national surveillance data, local health services market and cardiovascular drugs market estimation. “Cost ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... . Adverse events and adverse drug reactions of GEBA were recorded regardless of the conditions of stay ..."
 
Vol 10, No 1 (2017) PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM Abstract  similar documents
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
"... Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y ..."
 
Vol 10, No 2 (2017) CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... between the original and generic drugs, and to evaluate the treatment of acute diseases. With respect ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... . In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... drugs). The possibility of analyzing indirect and non-medical costs is also discussed. A dynamic version ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... and ribociclib that are included in Vital and Essential Drug List (VEDL) in combination with letrozole in first ..."
 
Vol 13, No 2 (2020) Prognosis of the influence of direct oral anticoagulants on the direct medical expenses in patients with atrial fibrillation Abstract  similar documents
S. V. Malchikova, A. N. Korobeinikova, N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva
"... will provide the purchase of additional modern drugs for patients. The cost-cutting reaches 12% for 5 years ..."
 
Vol 13, No 2 (2020) A modern conception of postcholecystectomy syndrome (based on the materials of the Advisory Board held on May 4, 2019 in Almaty, Kazakhstan) Abstract  similar documents
A. V. Nersesov, D. A. Kaibullaeva, O. S. Vasnev, L. K. Tashenova, M. M. Sakhipov, G. T. Berestimov, G. A. Akhmetzhanova, O. T. Ibekenov, M. O. Doskhanov, N. M. Zhumazhanov, Zh. M. Balzhanov, B. A. Aitmoldin, E. A. Toleubaev, E. M. Laryushina, K. N. Zhumagulov, G. N. Sobirova, S. I. Umarova, Yu. O. Shulpekova, A. V. Okhlobystin
"... -inflammatory drugs, prokinetics, nitrates, antispasmodics, calcium channel antagonists, botulinum toxin ..."
 
Vol 13, No 4 (2020) Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard Abstract  similar documents
I. Yu. Torshin, A. M. Lila, A. V. Naumov, A. Yu. Kochish, L. I. Alekseeva, E. A. Taskina, I. V. Sarvilina, A. N. Galustyan, A. N. Gromov, A. K. Khadzhidis, L. V. Vasilieva, E. F. Yevstratova, M. I. Udovika, O. A. Gromova
"... of the CG drug in OA). The effectiveness of therapy was assessed using the VAS, Lequesne, WOMAC scales ..."
 
Vol 13, No 4 (2020) Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system Abstract  similar documents
T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky
"... criteria for the reimbursement of medical technologies, including medicinal drugs. ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic study of nutrition support in the conditions of current health care system in Russia Abstract  similar documents
I. A. Metelkin, R. I. Yagudina
"... costs were taken into account: expenses for drug therapy, hospitalization (intensive care unit ..."
 
Vol 13, No 3 (2020) Economic burden of systemic sclerosis: systematic review Abstract  similar documents
D. L. Klabukova, V. S. Krysanova, T. N. Ermolaeva, M. V. Davydovskaya, K. A. Kokushkin
"... by direct medical costs for hospitalization and drug therapy and indirect costs were mostly associated ..."
 
Vol 13, No 4 (2020) The social-economic burden of spinal muscular atrophy in Russia Abstract  similar documents
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
"... were compiled into the model. The authors accounted for direct medical (diagnostics, drugs, surgery ..."
 
Vol 8, No 1 (2015) PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE Abstract  similar documents
D. V. Blinov, U. V. Zimovina, T. I. Ushakova
"... .3%), hypoglycemic – 457/2450 (18.7%) drugs. Lipotropic products administered at 319/2450 (13.0%) cases, detoxifying ..."
 
101 - 123 of 123 Items << < 1 2 3 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)